Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMMA: Fluoxetine ODT in Autism
NCT00787111Phase 3Terminated
- Sponsor
- Neuropharm
- Start
- Nov 2008
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fluoxetine in Autism Spectrum Disorder (ASD), sponsored by Neuropharm. Primary endpoint: Safety Outcomes at 18 months. Started Nov 2008; status: terminated.
02
Drugs
fluoxetine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT00787111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00787111.